The Frequency of Optimal Glycemic Control After Adding Sitagliptin on Treatment Regimen of Patient With Type 2 Diabetic

Background and Objectives Dipeptidyl peptidase-4 inhibitors (DPP4-I) including sitagliptin is a new therapeutic class of oral anti-hyperglycemic drugs for T2DM. The aim of this study was to evaluate the frequency of glycemic control after adding sitagliptin on treatment regimen of patient with type 2 diabetic. Subjects and Methods This cross-sectional study conducted on 120 patients with type 2 diabetes mellitus referring to diabetes clinic of Imam Hospital, Ahvaz in 2019-2020. Sitagliptin (100 mg/day) was added to the preexisting therapy for type 2 diabetes (metformin / metformin + gliclazide / metformin + insulin). Therapeutic effects and glycemic control (Changes in the glycated hemoglobin (HbA1c) level) after 3 months of treatment were compared with the baseline. Results The result of this study showed that after 3 months of treatment the level of FBS, BS-2h and HbA1C in 3 groups were significantly reduced compared with before treatment (P<0.0001), but the patients weight in the three groups were not significantly changed (P=0.568). There was no significant difference in the frequency of glycemic control between the patients treated with different concomitant drugs (P=0.501). The results revealed that patients younger age (P=0.041), shorter disease duration (P=0.021) and with higher HbA1c levels at baseline (P<0.0001) were likely to show more decreased in HbA1c levels. Conclusion Our study shows that sitagliptin (in combination with different type of treatment regimens) has the potential to improve glycemic control and prevent hypoglycemia and weight gain, and can be considered a useful drug in patients with type 2 diabetes mellitus.